Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 12/20 | 1.00 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
| ▸ | TACR1 | P25103 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13934076 | 1.00 | TGM2 (1.00) | TGM2CTSLCTSBCTSSCTSK | |
| SCHEMBL3015992 | 0.96 | TGM2 (0.93) | TGM2CTSLCTSBCTSSCTSK | |
| SCHEMBL1091124 | 0.96 | TGM2 (0.93) | TGM2CTSLCTSBCTSSCTSK | |
| SCHEMBL1091158 | 0.96 | TGM2 (0.93) | TGM2CTSLCTSBCTSSCTSK | |
| SCHEMBL1091157 | 0.96 | TGM2 (0.93) | TGM2CTSLCTSBCTSSCTSK | |
| SCHEMBL1091121 | 0.96 | TGM2 (0.93) | TGM2CTSLCTSBCTSSCTSK | |
| SCHEMBL9826132 | 0.93 | TGM2 (0.86) | TGM2CTSLCTSBCTSSCTSK | |
| SCHEMBL14070443 | 0.93 | TGM2 (0.86) | TGM2CTSLCTSBCTSSCTSK | |
| SCHEMBL4925942 | 0.93 | TGM2 (0.86) | TGM2CTSLCTSBCTSSCTSK | |
| SCHEMBL4950327 | 0.93 | TGM2 (0.86) | TGM2CTSLCTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235822-A1 | THERAPEUTICS FOR CANCER USING TGFB2 AND TGM6 | GMP BIOTECHNOLOGY LIMITED (CN) | 2025-11-13 | — | — | WO | claimed |
| US-5143925-A | Applying an inhibitor of the enzyme transglutaminase | GILETTE COMPANY, THE, A DE CORP. | 1992-09-01 | — | — | US | claimed |
| EP-0237082-B1 | 3,5-DISUBSTITUTED 4,5-DIHYDROISOXAZOLES AS TRANSGLUTAMINASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1991-05-29 | — | — | EP | claimed |
| US-4912120-A | Containing amine and amide substitution | SYNTEX (U.S.A.) INC. (US) | 1990-03-27 | — | — | US | claimed |
| EP-0237082-A2 | 3,5-disubstituted 4,5-dihydroisoxazoles as transglutaminase inhibitors | SYNTEX (U.S.A.) INC. (US) | 1987-09-16 | — | — | EP | claimed |
| WO-2025235822-A1 | THERAPEUTICS FOR CANCER USING TGFB2 AND TGM6 | GMP BIOTECHNOLOGY LIMITED (CN) | 2025-11-13 | — | — | WO | disclosed |
| CN-118806759-A | Systemic formulations of pyridone derivatives for TG2 related diseases | 福尔克博士药物有限责任公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20240287033-A1 | DEGRADERS OF TISSUE TRANSGLUTAMINASE 2 (TG2) | UNITED STATES GOVERNMENT | 2024-08-29 | — | — | US | disclosed |
| CN-115715187-B | Systemic formulations of pyridone derivatives for TG2 related diseases | 福尔克博士药物有限责任公司 | 2024-07-19 | — | — | CN | disclosed |
| EP-3965742-B1 | SYSTEMIC FORMULATION OF A PYRIDINONE DERIVATE FOR TG2-RELATED DISEASES | DR FALK PHARMA GMBH (DE) | 2023-06-14 | — | — | EP | disclosed |
| US-20230165845-A1 | SYSTEMIC FORMULATION OF A PYRIDINONE DERIVATE FOR TG2-RELATED DISEASES | ZEDIRA GMBH (DE) | 2023-06-01 | — | — | US | disclosed |
| CN-115715187-A | Systemic formulations of pyridone derivatives for TG 2-related diseases | 福尔克博士药物有限责任公司 | 2023-02-24 | — | — | CN | disclosed |
| US-7265093-B2 | Drug therapy for Celiac Sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265093-B2 | Drug therapy for Celiac Sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-09-04 | — | — | US | disclosed |
| WO-2007010201-A2 | MEDICAL DEVICES AND COATINGS THEREFOR | ASTON UNIVERSITY (GB) | 2007-01-25 | — | — | WO | disclosed |
| US-5143925-A | Applying an inhibitor of the enzyme transglutaminase | GILETTE COMPANY, THE, A DE CORP. | 1992-09-01 | — | — | US | disclosed |
| EP-0237082-B1 | 3,5-DISUBSTITUTED 4,5-DIHYDROISOXAZOLES AS TRANSGLUTAMINASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1991-05-29 | — | — | EP | disclosed |
| US-4929630-A | SKIN DISORDERS, ACNE, 4,5-DIHYDROISOOXAZOLE PEPTIDES | SYNTEX (U.S.A.) INC. (US) | 1990-05-29 | — | — | US | disclosed |
| US-4912120-A | Containing amine and amide substitution | SYNTEX (U.S.A.) INC. (US) | 1990-03-27 | — | — | US | disclosed |
| EP-0237082-A2 | 3,5-disubstituted 4,5-dihydroisoxazoles as transglutaminase inhibitors | SYNTEX (U.S.A.) INC. (US) | 1987-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165845-A1 | SYSTEMIC FORMULATION OF A PYRIDINONE DERIVATE FOR TG2-RELATED DISEASES | GLS2, GLS, SULT1E1 | TGM2 40/4885CTSL 2080/4885CTSB 2839/4885 |
| US-20240287033-A1 | DEGRADERS OF TISSUE TRANSGLUTAMINASE 2 (TG2) | PSMG3, UBE2G2, UBE2L3 | TGM2 18/4885CTSL 2666/4885CTSB 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.